IL-12, a proinflammatory cytokine with antitumor activity [59], was effective against ATC in a mouse xenograft model [60], and its administration inhibited tumor growth and prolonged survival by activating both CD8+ T and natural killer (NK) cells in a genetically engineered BRAFV600E mouse model [61]. This evidence concerns the gene CD8A and neoplasm.